Evidence map›Paper›PMID 40895943›Full record

ArticleCureus2025

Pulmonary Hypertension in Sickle Cell Disease: A Case Series.

Ngowari Pokima, Sunydip Gill, Ramtin Moradi, Aye M Thida, John Muthu

Abstract readCase Reports
In one paragraph

Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Ngowari PokimaInternal Medicine, Staten Island University Hospital, Northwell Health, Staten Isand, USA.
Sunydip GillInternal Medicine, State University of New York Downstate Health Sciences University, Brooklyn, USA.
Ramtin MoradiHematology and Oncology, State University of New York Downstate Health Sciences University, Brooklyn, USA.
Aye M ThidaHematology and Oncology, State University of New York Downstate Health Sciences University, Brooklyn, USA.
John MuthuDepartment of Medicine, Sickle Cell Division, Kings County Hospital Center, Brooklyn, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Pulmonary hypertension (PH) is a serious and increasingly recognized complication in sickle cell disease (SCD), particularly in individuals with the homozygous genotype. Elevated tricuspid regurgitant velocity (TRV) increases the potential for future development of PH, yet no standardized management approach currently exists, likely because of the varied pathophysiology of PH in these patients. Transthoracic echocardiogram-derived elevated TRV of more than 2.7 m/second in patients with SCD is associated with increased mortality and remains the only non-invasive approach to diagnosis. PH in patients with SCD can be due to various etiologies and can be considered either precapillary or post-capillary PH. This case series highlights the need to diagnose the underlying etiology of SCD-induced PH, which in turn will dictate appropriate management. Additionally, this case series will review recent management strategies available for treating patients with established PH and address significant risk factors for patients at risk for the development of PH.

Indexed as

complications of sickle cell diseasemultifactorial pulmonary hypertensionpulmonary hypertensionsickle cell hbscsickle cell trait-associated lung disease

Identifiers

PMID40895943
PMCPMC12394026

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.